Addex Therapeutics (XSWX:ADXN) Cash Flow for Dividends: CHF0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Addex Therapeutics Cash Flow for Dividends?

Addex Therapeutics XSWX:ADXN +3.45% Cash Flow for Dividends is CHF0.00 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Addex Therapeutics's cash flow for dividends for the three months ended in Mar. 2026 was CHF0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was CHF0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Addex Therapeutics Cash Flow for Dividends Related Terms

Addex Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Addex Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Addex Therapeutics Cash Flow for Dividends Chart

Addex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Addex Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Addex Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of CHF0.00 Mil mean?
Addex Therapeutics (XSWX:ADXN) has a Cash Flow for Dividends of CHF0.00 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Addex Therapeutics and its competitors.
Is Addex Therapeutics' Cash Flow for Dividends too high?
Addex Therapeutics' current Cash Flow for Dividends is CHF0.00 Mil.
How does Addex Therapeutics' Cash Flow for Dividends compare to VRTX and REGN?
Addex Therapeutics' Cash Flow for Dividends of CHF0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Addex Therapeutics and its competitors. Addex Therapeutics's current Cash Flow for Dividends is CHF0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (XSWX:ADXN) has a current Cash Flow for Dividends of CHF0.00 Mil. The current Cash Flow for Dividends is CHF0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Addex Therapeutics (XSWX:ADXN), the current Cash Flow for Dividends is CHF0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Addex Therapeutics Business Description

Address Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.